Background: Therapeutic aerosols are commonly used in mechanically ventilated patients. The position of the nebulizer in the ventilator circuit and the humidification of inhaled gases can influence the efficiency of aerosol delivery. We evaluated the effect of nebulizer position on the pulmonary bioavailability of nebulized ipratropium in ventilated patients without known preexisting respiratory disease.
Methods: The study included 38 mechanically ventilated and sedated patients after open heart surgery. Ipratropium (500 microg) was delivered by an ultrasonic nebulizer. Patients were randomized into 2 groups: the nebulizer positioned before the heat humidification system (group 1, n = 19) or at the end of the inspiratory limb before the Y-piece (group 2, n = 19). The amount of ipratropium in the urine collected during the 4 hours after drug administration was measured by mass spectrometry.
Results: There were no statistically significant differences in tidal volume or respiratory rate between groups. There were no significant differences between the 2 groups in the amount of drug excreted (group 1 vs 2: 13,237 +/- 2313 pg/mL vs 15,529 +/- 3204 pg/mL) or in pulmonary bioavailability (.9% +/- .1% vs 1.1% +/- .2%).
Conclusion: The position of the nebulizer in the ventilatory circuit had no effect on the pulmonary bioavailability of ipratropium.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.hrtlng.2008.12.005 | DOI Listing |
Alzheimers Dement
December 2024
Department of Neurosurgery, Clinical Neuroscience Research Center, Tulane University School of Medicine, New Orleans, LA, USA.
Background: SARS-CoV-2 causes a variety of neurological sequelae in COVID-19 survivors, including fatigue and cognitive dysfunction. Endothelial dysfunction is the unifying and central mechanism of COVID-19 illness and a major risk factor for vascular dementia (VaD). Endothelial dysfunction stems, in part, from an imbalance between nitric oxide (NO) generated by the endothelial nitric oxide synthase (eNOS) and reactive oxidant species produced by uncoupled-eNOS.
View Article and Find Full Text PDFJ Agric Food Chem
January 2025
Joint Research Center for Food Nutrition and Health of IHM, School of Plant Protection, Anhui Agricultural University, Hefei, Anhui 230036, China.
The use of unmanned aerial vehicle (UAV) has greatly improved pesticide effectiveness and control efficiency; however, the risk of inhalation exposure to pesticides caused by spray drift requires urgent attention. This study is the first to investigate residue distribution and inhalation exposure risk of airborne prothioconazole and its metabolite prothioconazole-desthio during UAV application. The maximum detected unit exposure of prothioconazole and prothioconazole-desthio in airborne particulate matter was 0.
View Article and Find Full Text PDFFront Pharmacol
December 2024
Department of Pharmacy, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Introduction: MRTX1133 is a selective and reversible small molecule inhibitor of KRAS (G12D), which significantly delays the progression of solid tumors. However, no study on the absorption, distribution, and excretion of MRTX1133.
Methods: A fast ultra-high performance liquid chromatography-tandem quadrupole mass spectrometry method was developed for the determination of MRTX1133 in rat plasma, tissue homogenate, and urine.
Int J Nanomedicine
January 2025
Department of Pharmacy, the Affiliated Hospital, Southwest Medical University, Luzhou, People's Republic of China.
Betulinic acid (BA) is a natural compound obtained from plant extracts and is known for its diverse pharmacological effects, including anti-tumor, antibacterial, anti-inflammatory, antiviral, and anti-atherosclerotic properties. Its potential in anti-tumor therapy has garnered considerable attention, particularly for the treatment of breast, lung, and liver cancers. However, the clinical utility of BA is greatly hindered by its poor water solubility, low bioavailability, and off-target toxicity.
View Article and Find Full Text PDFInt J Pharm
December 2024
Hacettepe University, Faculty of Medicine, Department of Histology and Embryology, 06100, Sıhhiye, Ankara, Turkey; METU MEMS Center, 06530, Ankara, Turkey. Electronic address:
Rapid progressing non-small cell lung adenocarcinoma (NSCLC) decreases treatment success. Cannabinoids emerge as drug candidates for NSCLC due to their anti-tumoral capabilities. We previously reported the controlled release of Arachidonylcyclopropylamide (ACPA) selectively targeting cannabinoid 1 (CB1) receptor in NSCLC cells in vitro.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!